Compare Abbott Laboratories (ABT) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Deutsche Bank AG — how do they compare? Abbott Laboratories trades at $110.24 (market cap $187.95B), while Deutsche Bank AG trades at $38.48 (market cap $71.96B). The key difference: Abbott Laboratories is far larger — about 2.6× Deutsche Bank AG's market cap, and Deutsche Bank AG pays the higher dividend (3.04%). Which is the better fit depends on your goals.
| ABT | DB | |
|---|---|---|
Market Cap | $187.95B | $71.96B |
Sector | Health | Financials |
52-Week High | $136.62 | $40.33 |
52-Week Low | $82.57 | $28.37 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Deutsche Bank (DB) trades at $38.27, up 0.55% today, with a bullish technical signal from moving averages. The stock shows a discounted valuation with a P/E of 10.07 and P/B of 0.79. Recent Q2 2026 earnings missed expectations at $0.66 per share versus $0.91, but revenue growth remains solid. The company announced a $1.00 dividend and a new share buyback program, supported by strong capital buffers and its recent designation as a clearing bank for China's renminbi (Reuters, 2026-08-10).
The outlook is mixed; strong operational performance and strategic initiatives like AI dealmaking (CNBC, 2026-07-29) offer upside, but earnings volatility and regulatory scrutiny (Reuters, 2026-07-22) pose risks. Analyst consensus is neutral with 57.58% hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
